Table 2.
Summary of results.
| Histological Subtype | Study Included | Number of patients | HER2 positivity estimate (95% CI) |
|---|---|---|---|
| Salivary duct carcinoma | 37 | 1105 | 43% (95% CI: 36% – 51%) |
| Carcinoma ex pleomorphic adenoma | 14 | 218 | 39% (95% CI: 32% – 45%) |
| Squamous cell carcinoma | 5 | 39 | 17% (7.5%-33%) |
| Adenocarcinoma NOS | 14 | 274 | 13% (7.6% – 21%) |
| Intraductal carcinoma | 1 | 9 | 11% (0.28% – 48%) |
| Poorly differentiated carcinoma | 4 | 15 | 6.7% (0.17%-32%). |
| Mucoepidermoid carcinoma | 15 | 591 | 5.5% (2.9% – 9.6%). |
| Myoepithelial carcinoma | 9 | 70 | 4.3% (1.4% – 13%) |
| Epithelial-myoepithelial carcinoma | 2 | 56 | 1.8% (0.04%-9.6%) |
| Acinic cell carcinoma | 10 | 274 | 0.45% (0.0097% – 18%) |
| Adenoid cystic carcinoma | 14 | 541 | 0.15% (0.037% – 5.4%) |
| Polymorphus adenocarcinoma | 3 | 50 | 0% |
| Basal cell carcinoma | 5 | 33 | 0% |
| Oncocytic carcinoma | 3 | 14 | 0% |
| Lymphoepithelial carcinoma | 2 | 5 | 0% |
| Clear cell carcinoma | 1 | 1 | 0% |
| Total | 50 | 3372 |